查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585543

良性前列腺增生治療藥物市場：依治療層級、治療方法、最終用戶分類 - 全球預測 2025-2030

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class (5-Alpha Reductase Inhibitor, Alpha-Blocker, Phosphodiesterase-5 Inhibitor), Therapy (Combination Drug Therapy, Mono Drug Therapy), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年良性前列腺增生治療市場價值為85.8億美元，預計2024年將達到91.7億美元，複合年成長率為6.97%，2030年將達到137.6億美元。

良性攝護腺增生 (BPH) 治療包括多種旨在緩解良性攝護腺增生症狀的醫療通訊協定。在醫療保健市場中，BPH 被定義為前列腺的非癌性腫大，主要影響 50 歲以上的男性並導致泌尿系統問題。嚴重的閉尿症、腎功能損害以及可能復發的尿道感染需要治療 BPH，早期治療非常重要。治療範圍從 α 受體阻斷劑和 5-α 還原酶抑制劑等藥物到手術介入和微創手術，如經經尿道前列腺切除術(TURP) 和雷射治療。最終用途主要是醫院、診所和門診手術中心。

主要市場統計
基準年[2023] 85.8億美元
預測年份 [2024] 91.7億美元
預測年份 [2030] 137.6億美元
複合年成長率（%） 6.97%

市場成長的推動因素包括男性人口老化、男性健康意識的提高、微創手術的進步以及聯合治療的普及。最近關注個人化醫療和新型藥物輸送系統開發的研究蘊藏著潛在的商機。此外，擴大新興國家的醫療保健服務範圍是一條開拓的道路。然而，高昂的治療成本、嚴格的監管要求以及某些治療的潛在副作用（如性功能障礙）等因素帶來了挑戰。

策略建議包括投資研究和開發副作用最小的創新療法，以及加強藥物和醫療設備的整合。保持嚴格的監管合規性並培養與醫療保健提供者的夥伴關係以提高市場滲透率也將是有利的。數位健康應用市場已經成熟，例如用於患者隨訪的遠端醫療諮詢和用於症狀監測的行動醫療應用程式，提供了潛在的創新領域。最終，了解客戶偏好並提高疾病意識和教育對於市場成功至關重要。整體而言，良性攝護腺增生治療市場的特點是在技術創新、人口趨勢和策略夥伴關係關係的推動下，具有中等至穩健的成長前景。

市場動態：揭示快速發展的 BPH 藥物市場的關鍵市場洞察

供需的動態交互作用正在改變良性前列腺增生藥物的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 良性攝護腺增生患者增加
    • 手術和藥物/治療方法核准的優惠報銷
    • 政府投資改善醫療基礎設施
  • 市場限制因素
    • 與良性攝護腺增生治療相關的副作用
  • 市場機會
    • 良性攝護腺增生微創治療的出現
    • 良性前列腺增生症的持續研究與開發
  • 市場挑戰
    • 缺乏治療功效

波特五力：駕馭 BPH 藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對良性前列腺增生藥物市場的影響

外部宏觀環境因素在塑造良性前列腺增生藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解良性攝護腺增生治療藥物市場的競爭狀況

對良性前列腺增生治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

良性前列腺增生藥物市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估良性前列腺增生藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃良性前列腺增生藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對良性前列腺增生藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 良性前列腺增生症的生長
      • 手術、藥物和治療核准的優惠報銷
      • 政府投資改善醫療基礎設施
    • 抑制因素
      • 與 BPH 治療相關的副作用
    • 機會
      • 良性攝護腺增生微創治療的出現
      • 良性前列腺增生症的持續研究與開發
    • 任務
      • 缺乏治療效果
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的良性攝護腺增生藥物市場

  • 5-α還原酶抑制劑
  • α阻斷劑
  • 磷酸二酯酶5抑制劑

第7章：良性攝護腺增生藥物市場治療

  • 伴隨藥物治療
  • 單一藥物治療

第8章良性攝護腺增生藥物市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第9章北美及南美良性前列腺增生藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太良性前列腺增生藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲前列腺增生藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Merck KGaA
  • Mylan NV
  • Pfizer, Inc.
  • Sanofi SA
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 8.58 billion in 2023, expected to reach USD 9.17 billion in 2024, and is projected to grow at a CAGR of 6.97%, to USD 13.76 billion by 2030.

Benign Prostatic Hyperplasia (BPH) treatment encompasses a variety of medical protocols aimed at alleviating the symptoms of an enlarged prostate. In the healthcare market, BPH is defined as non-cancerous enlargement of the prostate gland affecting primarily men over 50, causing urinary issues. The necessity of BPH treatment arises from the potential for severe urinary retention, kidney damage, and recurrent urinary tract infections, making early management critical. Treatments range from medications like alpha-blockers and 5-alpha-reductase inhibitors to surgical interventions and minimally invasive procedures such as transurethral resection of the prostate (TURP) and laser therapies. The application scope extends to pharmaceuticals, medical devices, and healthcare services sectors, with end-use primarily in hospitals, clinics, and ambulatory surgical centers.

KEY MARKET STATISTICS
Base Year [2023] USD 8.58 billion
Estimated Year [2024] USD 9.17 billion
Forecast Year [2030] USD 13.76 billion
CAGR (%) 6.97%

Market growth is driven by the aging male population, increasing awareness about men's health, advancements in minimally invasive procedures, and the burgeoning adoption of combination therapies. Recent research focusing on personalized medicine and the development of novel drug delivery systems holds potential opportunities. Furthermore, expanding healthcare access in emerging economies presents untapped avenues. However, factors such as high treatment costs, strict regulatory requirements, and potential side effects like sexual dysfunction in certain treatments pose challenges.

Strategic recommendations include investing in R&D for innovative treatments with minimal side effects and enhancing drug-device integration. Maintaining robust regulatory compliance and fostering partnerships with healthcare providers for improved market penetration can be advantageous. The market is ripe for digital health applications such as telemedicine consultations for patient follow-up and mobile health apps for symptom monitoring, offering potential areas of innovation. Ultimately, understanding customer preferences and promoting awareness and education about the condition is vital for market success. Overall, the BPH treatment market is characterized by moderate to robust growth prospects, hinged on technological innovation, demographic trends, and strategic partnerships.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growth in cases of benign prostatic hyperplasia
    • Favorable reimbursement for surgeries and drug and treatemnt approvals
    • Government investments in improving healthcare infrastructure
  • Market Restraints
    • Side-effects related to BPH treatment
  • Market Opportunities
    • Emergence of minimally invasive treatments for benign prostatic hyperplasia
    • Ongoing research & development regarding benign prostatic hyperplasia
  • Market Challenges
    • Lack of efficacy of treatments

Porter's Five Forces: A Strategic Tool for Navigating the Benign Prostatic Hyperplasia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Benign Prostatic Hyperplasia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Benign Prostatic Hyperplasia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Benign Prostatic Hyperplasia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Benign Prostatic Hyperplasia Treatment Market

A detailed market share analysis in the Benign Prostatic Hyperplasia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Benign Prostatic Hyperplasia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Benign Prostatic Hyperplasia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Benign Prostatic Hyperplasia Treatment Market

A strategic analysis of the Benign Prostatic Hyperplasia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Merck KGaA, Mylan N.V., Pfizer, Inc., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across 5-Alpha Reductase Inhibitor, Alpha-Blocker, and Phosphodiesterase-5 Inhibitor.
  • Based on Therapy, market is studied across Combination Drug Therapy and Mono Drug Therapy.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in cases of benign prostatic hyperplasia
      • 5.1.1.2. Favorable reimbursement for surgeries and drug and treatemnt approvals
      • 5.1.1.3. Government investments in improving healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects related to BPH treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of minimally invasive treatments for benign prostatic hyperplasia
      • 5.1.3.2. Ongoing research & development regarding benign prostatic hyperplasia
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of efficacy of treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. 5-Alpha Reductase Inhibitor
  • 6.3. Alpha-Blocker
  • 6.4. Phosphodiesterase-5 Inhibitor

7. Benign Prostatic Hyperplasia Treatment Market, by Therapy

  • 7.1. Introduction
  • 7.2. Combination Drug Therapy
  • 7.3. Mono Drug Therapy

8. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Benign Prostatic Hyperplasia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Asahi Kasei Corporation
  • 4. Astellas Pharma Inc.
  • 5. Boehringer Ingelheim GmbH
  • 6. Boston Scientific Corporation
  • 7. Eli Lilly and Company
  • 8. Endo International PLC
  • 9. GlaxoSmithKline plc
  • 10. Merck KGaA
  • 11. Mylan N.V.
  • 12. Pfizer, Inc.
  • 13. Sanofi S.A.
  • 14. Teleflex Incorporated
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COMBINATION DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MONO DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023